Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors
about
HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugsStructural and kinetic analysis of drug resistant mutants of HIV-1 proteaseInhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibodyCrystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistanceLack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 proteaseX-Ray Crystal Structures of Human Immunodeficiency Virus Type 1 Protease Mutants Complexed with AtazanavirMolecular recognition of cyclic urea HIV-1 protease inhibitorsStatistical potentials for fold assessment.Inhibition of human endogenous retrovirus-K10 protease in cell-free and cell-based assays.Genotypic testing for human immunodeficiency virus type 1 drug resistance.HIV-1 protease inhibitors in development.Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.Assays for HIV with improved sensitivity and specificity.Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses.Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 proteaseLooking at the proteases from a simple perspective.Solvation studies of DMP323 and A76928 bound to HIV protease: analysis of water sites using grand canonical Monte Carlo simulations.Differences in the interactions between the subunits of photosystem II dependent on D1 protein variants in the thermophilic cyanobacterium Thermosynechococcus elongatusFolded monomer of HIV-1 protease.Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.Resistance profiles of cyclic and linear inhibitors of HIV-1 protease.Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.Anti-human immunodeficiency virus drug combination strategies.Comparative study of some energetic and steric parameters of the wild type and mutants HIV-1 protease: a way to explain the viral resistance.Can cyclic HIV protease inhibitors bind in a non-preferred form? An ab initio, DFT and MM-PB(GB)SA studyIncorporating target heterogeneity in drug designNew HIV protease inhibitors for drug-resistant virusesResistance proof, folding-inhibitor drugs
P2860
Q24646227-0BB7EFD8-5B11-4755-86D1-12EACA809723Q27619254-120B5864-7039-4062-BC5A-823162393580Q27620967-B9150DAD-07DC-4CD7-9B99-6F62A4DCBB6AQ27628785-E10203F7-B4AE-41FA-852C-B891F6EE3703Q27637329-08BCF046-4839-45F8-ACE7-7F445A809331Q27645052-5B18682E-E9FC-4D83-9B08-0097C7913B3FQ27757042-ADBF8BA4-66E5-49DE-A576-D2073A56347BQ30329417-1EEA595D-13BA-43C6-B94B-3432D0904976Q30663203-CD289996-8E43-4AA7-B19F-EC276B58C91BQ33906239-6341FC75-4A6A-41FB-BF0A-EB8B872D02B8Q34544671-A8266D75-99D6-4833-BE44-7F4504446733Q34937254-4DACCCA9-6A60-4ED6-A0B2-978F35CA92B3Q36179798-280E60E1-FF9A-45A8-9C9E-F3247A44CFC0Q36376216-55F565C8-CCBF-410B-96BC-6C5AA1A2914FQ36639502-2EC375FF-C24B-40B4-ADFD-C9A2E63B69C4Q37848282-4073D713-8FC8-447B-A0B9-A80B360F9AD6Q41891194-8D561D7A-731C-4D7C-9E5A-F9FACCACAF8AQ42423837-1EFDE086-C491-4310-9469-D0230E2A3194Q43764692-EABF2D1C-96E8-4232-94F2-20D2009F8E9FQ43909316-71D3B358-9D3C-4409-8223-74B486CFC9DFQ44103468-316451A3-C960-45E1-A3A5-2E9A7FCED447Q44103766-72EAAE12-9B67-41F6-B173-D9AC34590A9FQ45752028-9C7F3D65-996E-4DC8-A77D-97A5AC8B823CQ48617328-EBAC6E93-2F3E-4796-AC38-A0DA246B5B98Q57647392-E04F6F88-11F0-4575-8DB5-DED4457E5254Q58023123-A99A1849-E321-4865-89BF-DCEDA9D73C87Q58389032-0E7D5F79-DD8B-4C54-A6F9-4D3AB71B51BBQ58882333-35DCEC22-862A-4D52-AEA7-55B5B02AA5D1
P2860
Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors
description
1997 nî lūn-bûn
@nan
1997 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Molecular basis of HIV-1 prote ...... ed with cyclic urea inhibitors
@ast
Molecular basis of HIV-1 prote ...... ed with cyclic urea inhibitors
@en
Molecular basis of HIV-1 prote ...... ed with cyclic urea inhibitors
@nl
type
label
Molecular basis of HIV-1 prote ...... ed with cyclic urea inhibitors
@ast
Molecular basis of HIV-1 prote ...... ed with cyclic urea inhibitors
@en
Molecular basis of HIV-1 prote ...... ed with cyclic urea inhibitors
@nl
prefLabel
Molecular basis of HIV-1 prote ...... ed with cyclic urea inhibitors
@ast
Molecular basis of HIV-1 prote ...... ed with cyclic urea inhibitors
@en
Molecular basis of HIV-1 prote ...... ed with cyclic urea inhibitors
@nl
P2093
P356
P1433
P1476
Molecular basis of HIV-1 prote ...... ed with cyclic urea inhibitors
@en
P2093
B D Korant
D D McCabe
E E Huston
R J DeLoskey
P304
P356
10.1021/BI962234U
P407
P577
1997-02-18T00:00:00Z